CASE WESTERN RESERVE UNIVERSITY
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1826-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- https://case.edu/dental
Clinical Trials
149
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (133 trials with phase data)• Click on a phase to view related trials
Developing Resilience and Anxiety Management Through the Arts
- Conditions
- AnxietyDepressionMood
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Case Western Reserve University
- Target Recruit Count
- 110
- Registration Number
- NCT07033052
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Community-Engaged Sleep Intervention for School-Aged Children With Autism Spectrum Disorder
- Conditions
- Behavioral Sleep and Circadian InterventionSleep DisturbanceAutism Spectrum Disorder
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Case Western Reserve University
- Target Recruit Count
- 50
- Registration Number
- NCT07007819
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
- Conditions
- SchizophreniaSchizo Affective DisorderSchizophreniform Disorders
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Case Western Reserve University
- Target Recruit Count
- 30
- Registration Number
- NCT07006935
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
- Conditions
- Urinary Tract Infections
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Case Western Reserve University
- Target Recruit Count
- 47
- Registration Number
- NCT06976125
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Nourishing Tomorrow: Role of Medically Tailored Groceries in Addressing Food Insecurity During Pregnancy
- Conditions
- Pregnancy RelatedPrematurityBirth Outcome, Adverse
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Case Western Reserve University
- Target Recruit Count
- 360
- Registration Number
- NCT06965530
- Locations
- 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸University Hospitals Rainbow Ahuja Women and Children's Center, Cleveland, Ohio, United States
🇺🇸Greater Cleveland Food Bank, Cleveland, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 30
- Next
News
Gabapentin Linked to Increased Dementia Risk in Chronic Pain Patients
A large medical records study found that receiving six or more gabapentin prescriptions for chronic low back pain was associated with 29% increased dementia risk and 85% increased mild cognitive impairment risk within 10 years.
NervGen Appoints Randall Kaye as Chief Medical Advisor Following Positive Spinal Cord Injury Trial Results
NervGen Pharma has appointed Dr. Randall Kaye as Chief Medical Advisor to guide the clinical and regulatory strategy for NVG-291, following positive topline results from the chronic cohort of their Phase 1b/2a spinal cord injury trial.
NSF Awards $500K Grant to Advance Synthetic DNA Nanoparticles for Targeted Gene Therapy
Dr. Divita Mathur at Case Western Reserve University received a prestigious NSF CAREER grant to develop synthetic DNA nanoparticles that can deliver therapeutic genes with precise targeting capabilities.
Trailhead Biosystems Secures $20M to Advance iPSC Technology for Drug Discovery and Regenerative Medicine
Trailhead Biosystems has raised $20 million in funding led by MAK Capital to enhance its portfolio of induced pluripotent stem cell (iPSC) derived cells for research applications.
American Heart Association Awards $1M to Study GLP-1 Medications' Impact on Cardiovascular Risk
The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.
Semaglutide Shows Promise for Slowing Biological Aging and Improving Cognition in HIV Patients
Semaglutide treatment slowed biological aging by approximately 9% and reduced epigenetic aging mortality risk by three years in HIV patients with lipohypertrophy over 32 weeks.
FDA Clears First Wireless, Catheter-Free Urodynamics System for Bladder Dysfunction Testing
The FDA has granted 510(k) clearance to Bright Uro's Glean™ Urodynamics System, the first wireless, catheter-free device for monitoring bladder dysfunction in patients with lower urinary tract conditions.
Novel Screening Technologies Enter Clinical Trial to Detect Silent Esophageal Precancer
University Hospitals and Case Western Reserve University launch an $8 million NIH-funded clinical trial to evaluate EsoCheck and EsoGuard technologies for detecting Barrett's Esophagus in non-GERD patients.
MedPacto Advances Vactosertib to Phase 2 Trial for Pediatric Osteosarcoma Treatment in US
MedPacto partners with leading US institutions, including Stanford University and Case Western Reserve University, to conduct Phase 2 trial of vactosertib for pediatric osteosarcoma treatment.
Semaglutide Associated with Reduced Alzheimer's Risk in Type 2 Diabetes Patients
A new study indicates that semaglutide, the active ingredient in Ozempic, may significantly reduce the risk of Alzheimer's disease in individuals with type 2 diabetes.